PT - JOURNAL ARTICLE AU - Laura M Guzmán-Rincón AU - Edward M Hill AU - Louise Dyson AU - Michael J Tildesley AU - Matt J Keeling TI - Bayesian Estimation of real-time Epidemic Growth Rates using Gaussian Processes: local dynamics of SARS-CoV-2 in England AID - 10.1101/2022.01.01.21268131 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.01.21268131 4099 - http://medrxiv.org/content/early/2022/01/26/2022.01.01.21268131.short 4100 - http://medrxiv.org/content/early/2022/01/26/2022.01.01.21268131.full AB - Quantitative assessments of the recent state of an epidemic and short-term projections into the near future are key public health tools that have substantial policy impacts, helping to determine if existing control measures are sufficient or need to be strengthened. Key to these quantitative assessments is the ability to rapidly and robustly measure the speed with which the epidemic is growing or decaying. Frequently, epidemiological trends are addressed in terms of the (time-varying) reproductive number R. Here, we take a more parsimonious approach and calculate the exponential growth rate, r, using a Bayesian hierarchical model to fit a Gaussian process to the epidemiological data. We show how the method can be employed when only case data from positive tests are available, and the improvement gained by including the total number of tests as a measure of heterogeneous testing effort. Although the methods are generic, we apply them to SARS-CoV-2 cases and testing in England, making use of the available high-resolution spatio-temporal data to determine long-term patterns of national growth, highlight regional growth and spatial heterogeneity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLGR, LD, MJT and MJK were supported by UKRI through the JUNIPER modelling consortium [grant number MR/V038613/1]. LD, MJT and MJK were supported by the Engineering and Physical Sciences Research Council through the MathSys CDT [grant number EP/S022244/1]. MJK, EMH and MJT were supported by the Biotechnology and Biological Sciences Research Council [grant number: BB/S01750X/1]. MJK was supported by the National Institute for Health Research (NIHR) [Policy Research Programme, Mathematical \& Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response; NIHR200411]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. MJK is affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at University of Liverpool in partnership with UK Health Security Agency (UKHSA), in collaboration with University of Warwick. MJK is also affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Genomics and Enabling Data at University of Warwick in partnership with UK Health Security Agency (UKHSA). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care or UK Health Security Agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics of the use of these data for these purposes was agreed by the UK Health Security Agency with the Government's SPI-M(O) / SAGE committees.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available to researchers with data sharing agreements in place with Public Health England.